Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

John L. Reagan, Rabin Niroula, Jessica McMahon, Pamela Egan, Inna Yakirevich, Mandy Pereira, Ari Pelcovits, Jeannine Margolis, Ashlee Sturtevant, Peter J. Quesenberry, Loren D. Fast

Blood (2023) 142 (Supplement 1): 6874.

https://doi.org/10.1182/blood-2023-177759

Published: 2023

Journal Articles

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Adam Zayac, MD, Pamela C Egan, MD, Thomas A Ollila, MD, Adam J Olszewski, MD, Peter Barth, MD, Matthew I. Quesenberry, MD, James Butera, MD, Loren D. Fast, PhD, Rabin Niroula, MBBS, Peter J. Quesenberry, MD, John L Reagan, MD

Blood (2019) 134 (Supplement_1): 4460.

https://doi.org/10.1182/blood-2019-123789

Published: 2019

Journal Articles

Inactivation of Human Leukocytes in Platelet Products After Pathogen Reduction Technology Treatment in the Presence of Platelet Additive Solution.

Loren D. Fast, PhD, Susanne Marschner, Ph.D., Gilbert DiLeone, Ph.D., Raymond Goodrich, PhD

Blood (2009) 114 (22): 2116.

https://doi.org/10.1182/blood.V114.22.2116.2116

Published: 2009

Journal Articles

Non-Engraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism

Gerald A. Colvin, DO, David Berz, Muthalagu Ramanathan, MD, Eric Winer, MD, Loren D. Fast, PhD, Gerald Jay Elfenbein, MD, Peter J. Quesenberry, MD

Blood (2008) 112 (11): 831.

https://doi.org/10.1182/blood.V112.11.831.831

Published: 2008

Journal Articles

Inactivation of Human White Blood Cells in Red Blood Cell Products Using the MIRASOL® System for Whole Blood.

Loren D. Fast, PhD, Susanne Marschner, Ph.D., Gilbert DiLeone, Ph.D., Suzann Doane, B.S., Christy Fitzpatrick, B.S., Goodrich Ray, Ph.D.

Blood (2007) 110 (11): 2897.

https://doi.org/10.1182/blood.V110.11.2897.2897

Published: 2007

Journal Articles

Inactivation of Human White Blood Cells in Red Blood Cell Products Using Mirasol® Pathogen Reduction Technology (PRT).

Loren D. Fast, PhD, Susanne Marschner, Ph.D., Gilbert DiLeone, Ph.D., Suzann K. Doane, B.S., Raymond P. Goodrich, Ph.D.

Blood (2006) 108 (11): 4135.

https://doi.org/10.1182/blood.V108.11.4135.4135

Published: 2006

Journal Articles

Recipient elimination of allogeneic lymphoid cells: donor CD4 + cells are effective alloantigen-presenting cells

Loren D. Fast

Blood (2000) 96 (3): 1144–1149.

https://doi.org/10.1182/blood.V96.3.1144

Published: 2000

NARROW

Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Inactivation of Human Leukocytes in Platelet Products After Pathogen Reduction Technology Treatment in the Presence of Platelet Additive Solution.

Non-Engraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism

Inactivation of Human White Blood Cells in Red Blood Cell Products Using the MIRASOL® System for Whole Blood.

Inactivation of Human White Blood Cells in Red Blood Cell Products Using Mirasol® Pathogen Reduction Technology (PRT).

Recipient elimination of allogeneic lymphoid cells: donor CD4 + cells are effective alloantigen-presenting cells

Email alerts

ASH Publications

American Society of Hematology

Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Inactivation of Human Leukocytes in Platelet Products After Pathogen Reduction Technology Treatment in the Presence of Platelet Additive Solution.

Non-Engraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism

Inactivation of Human White Blood Cells in Red Blood Cell Products Using the MIRASOL® System for Whole Blood.

Inactivation of Human White Blood Cells in Red Blood Cell Products Using Mirasol® Pathogen Reduction Technology (PRT).

Recipient elimination of allogeneic lymphoid cells: donor CD4 + cells are effective alloantigen-presenting cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only